Adlai Nortye Ltd. ADR (ANL) Stock

Adlai Nortye Ltd., a clinical-stage biotechnology firm, is dedicated to pioneering cancer therapies with operations spanning the United States and Mainland China. At the forefront of its portfolio is AN2025, a pan-phosphoinositide 3-kinase inhibitor currently advancing through Phase III clinical trials. This innovative treatment is specifically tailored for recurrent or metastatic head and neck squamous cell carcinomas, aiming to address significant unmet medical needs in oncology.

In addition to AN2025, Adlai Nortye Ltd. is actively developing AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is currently undergoing Phase Ib clinical trials for various cancers, including recurrent non-small cell lung cancer, urothelial cancer, triple-negative breast cancer, colorectal cancer, and cervical cancer after standard treatments. The company's pipeline also includes AN4005, an oral small-molecule PD-L1 inhibitor in Phase I clinical trials, which disrupts PD-1 and PD-L1 interactions to enhance immune response.

Founded in 2004 and headquartered in Grand Cayman, the Cayman Islands, Adlai Nortye Ltd. continues to expand its innovative research efforts. Preclinical candidates like AN8025, AN1025, and AN9025 underscore the company's commitment to advancing multifunctional antibodies and small molecule therapies targeting critical pathways in cancer biology. With a strategic focus on transformative oncology treatments, Adlai Nortye Ltd. aims to redefine standards of care and improve outcomes for patients worldwide.